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Abstract 
Background 
There is uncertainty as to whether alterations in glutamatergic function in affective disorders 
differ between unipolar and bipolar disorders and between depressive and euthymic states. 
Additionally, there are currently no available blood-based markers of central glutamatergic 
function to support clinical diagnosis and aid brain based investigations.  
Methods 
In this study, we measured levels of glutamate in the dorsal anterior cingulate cortex in-vivo 
using 1H-Magnetic Resonance Spectroscopy in medication free unipolar and bipolar patients 
(n=29, 20 unipolar and 9 bipolar) experiencing a major depressive episode, in comparison 
with a group of matched healthy controls (n=20). We also analysed peripheral glutaminase 
measured in serum to examine the relationship between central and peripheral measures.  
Results 
Anterior cingulate glutamate levels were reduced in both unipolar and bipolar depression 
groups relative to healthy controls, although this only reached significance in the unipolar 
group. Peripheral glutaminase levels did not differentiate bipolar from unipolar depression and 
a positive correlation with central glutamate levels did not reach statistical significance.  
Limitations 
The sample of bipolar disorder patients was relatively small due to the difficulties involved in 
finding medication-free patients experiencing a depressive episode. 
Conclusions 
These results suggest that glutamatergic hypofunction might represent a state marker for a 
depressive episode irrespective of diagnosis. Peripheral glutaminase did not index central 
glutamate levels in this study, which could potentially reflect a small magnitude of the effect 
requiring larger samples for detection.  
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Introduction 
Major depression and bipolar disorder are common conditions with substantial negative 
consequences for sufferers (Kessler et al., 2003; Merikangas et al., 2007). Understanding the 
biological changes associated with these conditions is a major research priority, and a better 
understanding of their biological basis could lead to improved diagnosis and treatment.  
Over the last two decades, neuroimaging has brought a deeper understanding of 
neurobiological alterations associated with these conditions, and researchers are moving 
towards developing these methods to diagnose and treat affective disorders (Wise et al., 
2014). In particular there is now a substantial literature detailing neurochemical abnormalities 
in both major depression and bipolar disorder (Arnone et al., 2015a; Shrestha et al., 2012; 
Taylor, 2014), and research into glutamatergic neurotransmission specifically has been 
pursued with increasing interest spurred by studies demonstrating that ketamine, an NMDA 
receptor antagonist, is associated with a rapid (albeit not sustained in the long term) 
improvement in symptoms in both both unipolar and bipolar depression (McGirr et al., 2015). 
This research has been aided by developments in magnetic resonance spectroscopy (MRS), 
a method that allows non-invasive measurement of glutamate and glutamine levels in vivo.  
Despite this, findings at present are inconsistent, and there are particularly divergent results 
from studies in major depression and bipolar disorder (Taylor, 2014). Glutamate and glutamine 
levels are typically found to be reduced in unipolar depression, most notably in prefrontal 
regions such as the anterior cingulate cortex (Arnone et al., 2015), while studies in bipolar 
disorder suggest an increase in glutamate in this region (Taylor, 2014). These results are 
difficult to reconcile with the efficacy of ketamine in treating both unipolar and bipolar 
depression. In particular, given the tendency of ketamine to increase glutamate levels (Stone 
et al., 2012), it is unclear why such a manipulation would improve depressive symptoms in 
bipolar disorder if it is indeed associated with increased glutamatergic tone. One possible 
explanation for these contradictory results is that studies examining glutamate levels in these 
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disorders have typically used voxels placed in the perigenual anterior cingulate cortex, an area 
in which glutamate levels appear to be unaffected by ketamine administration (Taylor et al., 
2012). Ketamine however appears to have marked effects in a more dorsal region of the 
anterior cingulate cortex (Stone et al., 2012) and it is possible that it is in this region that it 
exerts antidepressant effects. 
Additionally, while MRS provides an accurate measure of brain glutamate concentration in 
vivo, the identification of an easily measurable peripheral marker of glutamatergic function 
capable of indicating an affective state would simplify the use of glutamate as a diagnostic or 
treatment marker. One marker of particular interest is glutaminase, an enzyme that catalyses 
the conversion of glutamine to glutamate. Genetic variation in the GLS1 gene, which codes 
for glutaminase, is associated with levels of central glutamate and glutamine as measured 
using MRS (Öngür et al., 2011), indicating that glutaminase may be a marker of brain 
glutamate levels.  
Here we measured glutamate levels in a group of individuals with unipolar and bipolar major 
depression in the same voxel location where ketamine has been shown to affect glutamate 
levels (Stone et al., 2012). We predicted a reduction in glutamate levels associated with 
depressive state irrespective of affective diagnosis. Additionally, we measured peripheral 
glutaminase in serum and investigated changes in relation to brain glutamate. We 
hypothesised that peripheral glutaminase levels would positively correlate with anterior 
cingulate cortex glutamate levels. Importantly, we used a sample of medication-free patients 
to ensure that results were not influenced by current pharmacotherapy. 
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Methods 
Participants 
Participants were recruited through public advertisements and from local psychological 
therapy services (Wise et al., 2016a). Patients met DSM-IV criteria for a current major 
depressive episode in the context of unipolar or bipolar disorders determined by a clinical 
interview with a psychiatrist based on the Mini International Neuropsychiatric Interview (MINI, 
Sheehan et al., 1998). Patients with any other DSM-IV diagnoses were excluded. Healthy 
volunteers did not meet criteria for any current or past psychiatric diagnoses, as assessed by 
the MINI, and reported no family psychiatric history in first-degree relatives. Patients were 
enrolled if they experienced 1) moderate to severe depressive symptoms (score of ≥18) 
established with the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS, 
Montgomery & Asberg, 1979); 2) were psychotropic medication-free for ≥2 weeks (≥4 weeks 
for fluoxetine) and were not receiving any psychological intervention; and 3) did not experience 
current clinically significant symptoms of elation established by using the Young Mania Rating 
Scale (Young et al., 1978).  Diagnoses of bipolar disorder were retrospective and 
supplemented by review of medical notes and collateral information where necessary. Historic 
hypomanic symptoms were assessed using the Hypomania Checklist 33-item (Angst et al., 
2005; Feng et al., 2016). All participants were excluded if they reported any illicit substance 
use in the previous two months, had any physical health conditions or received 
pharmacotherapy that could affect safety, or interfere with data acquisition, analyses or 
interpretation. All participants were screened for MRI safety. The research was approved by 
the relevant local ethics committee and informed consent was obtained from each participant. 
Participants received a small financial compensation for taking part in the research. 
Magnetic resonance spectroscopy 
1H-Magnetic resonance spectroscopy data were acquired using a GE MR-750 3T system with 
a 12-channel head coil. A water supressed PRESS sequence was used (TR=3s, TE=30ms). 
 6 
As in previous work (Stone et al., 2012), a 20 x 20 x 20mm voxel was placed 16mm above the 
most anterior portion of the corpus callosum, on the midline, adjusted manually to ensure 
optimal coverage of grey matter. This resulted in coverage of the dorsal portion of Brodmann 
areas 24 and 32 (Figure 1). T1-weighted structural images were also collected to provide 
measures of intracranial volume (Echo time = 3.02ms, repetition time = 7.31ms, inversion time 
= 400ms, flip angle = 11°, 270mm x 270mm field of view, 196 slices. slice thickness = 
1.2mm)(Jack et al., 2010).  
Analysis of the MRS spectra was conducted using LCModel version 6.3 (Provencher, 2001), 
and spectra were visually inspected to ensure that the LCModel fit was acceptable. Glutamate 
concentrations were normalised to creatine to account for individual differences in the absolute 
volumes of metabolites.  
Glutaminase measurement 
To measure glutaminase levels in serum samples a commercial Enzyme-linked 
Immunosorbent Assay Kit for Glutaminase (Cloud-Clone Corp, Buckingham, UK) was used 
according to the manufacturer’s instructions. The protein glutaminase standard was diluted in 
standard diluent to generate a standard curve with seven points, ranging from 0.312 to 20 
ng/ml. Subsequently, 100 μl of prepared standards and samples (serum dilution 1:10) was 
added to the wells of the immunoassay plate pre-coated with a specific antibody against 
glutaminase and incubated at 37 °C for 2 h. The primary and secondary antibodies (1:100 
dilution) were added to the wells and incubated at 37 °C for 1 h and 30 min respectively. 
Subsequently, 100 μl of 3,3′,5,5′-tetramethylbenzidine substrate (TMB) were added to each 
well and incubated for 15 min in the dark. Finally, 100 μl of Stop Solution was added and 
absorbance was measured at 450 nm with a microplate photometric reader (DV990BV4, GDV, 
Milan, Italy). Sample concentration was calculated by interpolating the sample measurement 
in the standard curve. The sensitivity of the human glutaminase ELISA kit was determined to 
be 0.312 ng/ml. Human glutaminase ELISA kit is specific for glutaminase and has been 
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certified for the detection of human glutaminase. Blood samples were unable to be collected 
from one subject in the unipolar depression group and this subject was excluded from 
analyses involving glutaminase levels. 
Intracranial volume 
We compared intracranial volumes between groups to ensure that any group differences were 
not reflective of global alterations in brain volume. Intracranial volume was calculated by 
segmenting T1-weighted structural images from each subject using FreeSurfer 
(www.freesurfer.net).   
Statistical analysis 
All statistical analyses were performed using R (www.r-project.org). To assess whether 
depressed patients differed from controls we compared glutamate levels between both 
depressed groups combined and controls using an independent measures t-test, adjusted for 
age and sex. To test whether there were any differences between unipolar and bipolar 
depression, we compared the patient groups against one another using an independent 
measures t-test. To further explore diagnostic differences in central glutamate levels we used 
a one-way ANCOVA with age and sex as covariates. Significant effects were further explored 
using t-tests, corrected for multiple comparisons with the Benjamini-Hochberg method 
(Benjamini and Hochberg, 1995). Correlations between glutamate levels and clinical variables 
and peripheral markers were analysed using partial Pearson correlations, correcting for age 
and sex.  
 
Results 
Participants 
Twenty-nine patients with major depression (20 with unipolar and nine with bipolar disorder) 
and 20 healthy controls, matched on age, sex and handedness took part in the study. Of those 
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with bipolar disorder, seven had bipolar disorder type II, and two had type I.  Demographic 
and clinical details for the combined depressed group, as used in further analyses, are 
described in Table 1.  
Magnetic resonance spectroscopy 
The combined unipolar and bipolar depressed group had significantly lower glutamate levels 
in the anterior cingulate cortex than healthy volunteers (t(46.62) = -2.82, p = 0.014, d = - 0.79). 
To test our hypothesis that this was not an effect of diagnosis, we compared unipolar vs. 
bipolar groups and found no significant difference in glutamate levels (t(12.63) = -0.07., p = 1, 
d = -0.03). Total intracranial volume did not differ between controls and the depressed group 
(t(41.60) = -1.71, p = 0.20) or between unipolar and bipolar depression (t(18) = 0.23, p = 1, 
suggesting that this was not related to global brain volume. We also investigated potential 
differences in voxel composition that could affect our results by comparing grey matter volume 
within the voxel. This showed no significant differences between depressed patients and 
controls (t(45.16) = -0.66, p = .50, d = -0.19) or between depressed groups (t(19.57) = -2.20, 
p = 0.08, d = -0.8). Finally, to verify whether the observed reduction in glutamate was likely to 
be attributable to glutamine rather than glutamate per se, we repeated the critical comparison 
of patients versus controls by analysing Glx, a combined measure of glutamate and glutamine, 
and this showed no significant difference between groups (t(45.16) = -0.66, p = 0.50, d = -
0.19).  
We performed further exploratory analyses to investigate potential effects of diagnosis. A one-
way ANCOVA revealed a main effect of diagnosis on glutamate levels (F(2, 46) = 3.72, p = 
0.032, η2 = 0.14, Figure 2). Post-hoc tests showed that the unipolar group had significantly 
reduced glutamate levels relative to controls (t(38) = -2.63, p = 0.03, d = -0.90). The bipolar 
group had reduced levels of glutamate relative to controls of similar effect size, but this was 
not statistically significant (t(27) = -1.75, p = 0.14, d = -0.70).  
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There was no significant correlation between glutamate levels and depression severity, as 
measured by the MÅDRS, in the combined depressed group (Rpartial(25) = 0.034, p = 0.87). 
There was also no correlation between glutamate levels and self-reported hypomanic 
symptoms measured using the hypomania checklist (Rpartial(23) = 0.011, p = 0.62). 
Relationship between glutamate function and peripheral glutaminase 
There were no differences in glutaminase levels between the combined unipolar and bipolar 
depressed groups and controls (t(28.3) = -1.21, p = 0.48, d  = -0.39) or between unipolar and 
bipolar disorders (t(13.76) = -0.96, p = 0.72, d = -0.40). Analysis of the relationship between 
prefrontal glutamate levels and peripheral glutaminase indicated a positive but non-significant 
correlation between these measures (Rpartial(48) = 0.25, p = 0.09, Figure 3).  
 
Discussion 
We measured dorsal anterior cingulate cortex glutamate levels in unmedicated unipolar and 
bipolar major depression and found that glutamate was reduced relative to controls in the 
depressive state irrespective of diagnosis, although this effect only reached significance in the 
numerically larger unipolar group. Additionally, our results suggest that alternatives to 
peripheral glutaminase levels may be preferable to index central glutamate levels. 
Our finding of reduced glutamate in unipolar depression is in line with previous research 
indicating glutamatergic hypofunction in unipolar depression (Arnone et al., 2015a). In bipolar 
disorder the majority of studies tend to indicate an increase in glutamate levels in the prefrontal 
cortex (Taylor, 2014), which contrasts with our finding of a reduction in glutamate levels. 
Although this reduction was not statistically significant, given the challenges associated with 
recruiting medication-free individuals with bipolar depression and the resulting issues with 
statistical power, it is important to consider these results in the context of previous research in 
similar patients. The only other study to date to investigate anterior cingulate cortex glutamate 
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levels in medication-free bipolar disorder patients currently experiencing a depressive episode 
also reported a non-significant reduction in glutamate in the anterior cingulate cortex (Xu et 
al., 2013) and our results, taken together with this previous work, suggest that bipolar 
depression in the absence of medication may be associated with glutamatergic hypofunction. 
A reduction in glutamate levels as an expression of state rather than diagnosis concords with 
the clinical efficacy of ketamine in both unipolar and bipolar depression, known to increase 
glutamate levels in the region investigated in this study (Stone et al., 2012).  In addition, 
topographical differences in prefrontal voxel placement might explain discrepancies between 
our findings and the literature. Most studies have used voxels placed in the perigenual anterior 
cingulate cortex, an area less affected by ketamine administration (Taylor et al., 2012). 
Nevertheless, it is not possible to determine the exact contributions of the unmedicated status 
of the patients and the voxel placement to the differences observed between our results and 
those of previous studies. These will be important questions for future research to address. In 
particular, the effects of traditional pharmacotherapy for unipolar and bipolar depression on 
glutamatergic function are poorly understood.  
The absence of a significant difference in peripheral glutaminase levels in subjects with 
unipolar and bipolar depression vs. healthy controls suggests that variations in this enzyme 
might not necessarily reflect diagnostic differences in central glutamate levels. Additionally, 
the positive correlation between peripheral glutaminase levels and MRS-measured 
glutamatergic function did not reach statistical significance in our analysis. The finding might 
suggest that peripheral glutaminase does not reflect glutamatergic neurotransmission in the 
anterior cingulate cortex. This would be in agreement with preliminary studies in healthy 
individuals that measured glutamatergic function with MRS in a different location within the 
medial prefrontal cortex (Shulman et al., 2006). Alternatively, the trend towards significance 
in the correlation between peripheral glutaminase levels and MRS-measured glutamatergic 
function might reach significance in studies with larger samples. Further research with higher 
statistical power are required to confirm or reject our finding.  
 11 
The most important implication of this work is that it provides a putative explanation for the 
effectiveness of fast acting glutamatergic agents such as ketamine, known to increase cortical 
glutamate release, in treating major depressive episodes (Rowland et al., 2005; Stone et al., 
2012). Ketamine has been shown to be effective in both unipolar and bipolar depression 
(McGirr et al., 2015), and these results have been difficult to fully understand in the context of 
research showing increased glutamate levels in bipolar disorder (Taylor, 2014). We propose 
that the region within the prefrontal cortex centred around Brodmann area 32 might be key to 
understanding glutamatergic function in affective disorders. Notably, this region has been 
implicated in the processing of negative affect (Tolomeo et al., 2016), and the presence of 
glutamatergic hypofunction in this area may contribute to disturbances in affective regulation. 
This phenomenon is likely to be mediated by an increased baseline GABAergic interneuron 
tone, known to modulate glutamatergic hypofunction (Stone et al., 2012). In this context, 
ketamine may act by inhibiting GABAergic interneurons, resulting in increased glutamatergic 
release as demonstrated in healthy controls (Stone et al., 2012). Although these results are 
promising it is important to acknowledge that the literature on the glutamatergic effects of 
ketamine in humans is limited in both its extent and methodological rigour. The study by Stone 
and others (Stone et al., 2012), for example, was not placebo controlled. This means that its 
results must be interpreted with caution and that future work could employ a placebo controlled 
crossover design in healthy individuals or a pre-post treatment investigation in patients with 
both unipolar and bipolar depression to confirm our results.  
It is also possible that decreased levels of glutamate in this region is a reflection of grey matter 
volume reduction, which we have recently demonstrated in both unipolar and bipolar 
depression (Arnone et al., 2016; Wise et al., 2016c). This seems unlikely however, as we used 
ratios of glutamine to creatine so that our results should not be a direct effect of reduced grey 
matter volume. Another factor to consider is that a reduction in the integrity of the white matter 
callosal pathways connecting the two hemispheres in affective disorders might also affect 
glutamatergic function (Wise et al., 2016b). This would be in agreement with recent theories 
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suggesting that the metabolic interplay between glutamatergic neurons and astrocytes in the 
synapse might be central to understanding abnormalities in this neurotransmitter in affective 
disorders and could potentially contribute to the therapeutic effects of fast acting 
antidepressants (Arnone et al., 2015b). 
Our findings indicate that the dorsal anterior cingulate cortex appears to be central to 
understanding the role of glutamatergic neurotransmission in affective disorders. Further 
investigations dissecting the functional neuroanatomy of this region are warranted, particularly 
in relation to the role played by GABAergic interneurons. Parvalbumin expressing GABAergic 
interneurons projecting from the medio-dorsal thalamic nucleus to the prefrontal cortex appear 
crucially important to investigate in future studies as they play a critical role in modulating the 
functional flexibility of the dorsal part of the anterior cingulate cortex when integrating sensory 
information (Delevich et al., 2015), and are regulated by glutamatergic neurotransmission 
(Homayoun and Moghaddam, 2007). Newly developed methods of spatially mapping 
glutamate may prove valuable in this respect (e.g. Cai et al., 2013).  
The exclusion of the effects of pharmacological or psychological therapies on the data is a 
strength of this study. Although we cannot entirely exclude effects of previous treatments, we 
can be confident that our results are not an effect of current treatment. Additionally, many of 
our patients in the unipolar group were experiencing their first depressive episode and results 
are unlikely to represent “scar” effects. Diagnoses were also thoroughly examined for all 
patients to ensure that cases were not inappropriately classified.  
Limitations include the small number of bipolar participants due to the difficulty of recruiting 
unmedicated, currently depressed, patients with this condition. Hence it is important to 
consider our findings in the context of previous research demonstrating a similar effect in 
unmedicated bipolar depression (Xu et al., 2013). The community sample we included in the 
research reflects a lower severity index than an inpatient sample or more complex forms of 
illness with comorbidities, which we excluded. Also, the bipolar sample most entirely 
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comprised patients with bipolar type II. Hence, it is not possible to generalise findings to bipolar 
type I. For this reason we cannot entirely exclude the possibility that more severe cases and/or 
psychotic presentations may differ in relation to glutamatergic function, perhaps similarly to 
glutamatergic and morphometric alterations observed in schizophrenia (Arnone et al., 2009; 
Merritt et al., 2016). It is also not possible to comment on specific state effects as we did not 
include groups of patients experiencing euthymia or elated mood.  
We also did not observe any reduction in Glx, a combined measure of glutamate and 
glutamine. It is possible that this is due to a less precise estimate of glutamine measurements 
at this field strength (Henry et al., 2011). Additionally, it is theoretically possible that our use 
of normalised glutamate levels (with creatine as a reference) introduced a bias if differences 
in the reference metabolite were present. Results from a recent meta-analysis however 
provide some reassurance by suggesting that differences in absolute levels of creatine do not 
significantly differ between patients with major depression and healthy controls (Arnone et al., 
2015b).  
In summary, we investigated glutamate levels in the dorsal anterior cingulate cortex in 
unmedicated subjects with bipolar and unipolar depression and demonstrated glutamatergic 
hypofunction in unipolar depression, with a trend towards a significant reduction in bipolar 
depression.  Evaluation of circulating glutaminase indicated the need for larger studies to 
discard its utility or identification of an alternative proxy for central brain glutamate if accessible 
biomarkers for disease-related alterations in central glutamate are to be developed. 
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 Major Depression Healthy control p 
Number 29 20 NA 
Mean age in years (SD) 30.14 (7.04) 30.05 (6.71) 0.97 
Sex: male, female 6, 23* 2, 18 0.32 
MÅDRS, mean (SD) 26.59 (4.59) 0.95 (1.39) < .001 
YMRS, mean (SD) 2.21 (1.82) 0.1 (0.31) < .001 
Mean duration of illness in years (SD) 7.65 (6.40) - - 
Median number of depressive episodes (SD)** 5.66 (11.94) - - 
Mean total intracranial volume in ml (SD) 1425.89 (144.90) 1447.76 (113.11) 0.56 
Table 1: Demographic and clinical information for all participants. Values are reported as 
mean (SD), except the number of episodes which is reported as median (SD) due to skewed 
data. P values in the table refer to comparison between the combined depressed group and 
healthy controls. MÅDRS: Montgomery-Åsberg Depression Rating Scale, YMRS: Young 
Mania Rating Scale; NA: Not Applicable. *Patients with bipolar depression had a higher 
proportion of males than the other groups (Χ2 = 4.49, p = 0.034). **The bipolar group had 
experienced significantly more depressive episodes (W = 34.5, p = 0.007, non-parametric test 
used for non-normally distributed data). There were no other clinically significant differences 
between unipolar and bipolar groups. 
 
 
Figure 1: Illustration of anterior cingulate cortex MRS voxel location on a typical participant 
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Figure 2: Glutamate levels in anterior cingulate cortex of healthy controls, people with unipolar 
depression, and bipolar depression. Coloured areas represent a histogram of the data in each 
conditions, while circles represent the individual data points. Dashed lines represent means 
and standard errors. 
 
 
Figure 3: Relationship between peripheral glutaminase levels and anterior cingulate 
glutamate measured using MRS. 
 
 
